Logo
x

Search

Subscribe Now

Pipeline

Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

  • March 9, 2021
Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

  • February 25, 2021
Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

  • July 27, 2020
Audentes Signs an Exclusive License Agreement with Nationwide Children's Hospital (NCH) for the Expansion of its AAV Technology and Pipeline

Audentes Signs an Exclusive License Agreement with Nationwide Children's Hospital (NCH) for the Expansion of its AAV Technology an...

  • April 9, 2019
Novartis Reports Acquisition of MorphoSys for ~$2.9B

    Novartis Reports Acquisition of MorphoSys for ~$2.9B

    • February 6, 2024
    Sanofi Acquires Inhibrx for ~$2.2B, Adding INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD) to its Pipeline

      Sanofi Acquires Inhibrx for ~$2.2B, Adding INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD) to its Pipeline

      • January 23, 2024
      SOTIO Entered into a License Agreement with Synaffix to Expand ADC Pipeline

        SOTIO Entered into a License Agreement with Synaffix to Expand ADC Pipeline

        • October 16, 2023
        BMS to Acquire Mirati Therapeutics for ~$5.8B

          BMS to Acquire Mirati Therapeutics for ~$5.8B

          • October 9, 2023
          Pipeline Therapeutics Entered into a Global License and Development Agreement with Janssen for PIPE-307 to Treat Nervous System Disorders

            Pipeline Therapeutics Entered into a Global License and Development Agreement with Janssen for PIPE-307 to Treat Nervous System Di...

            • April 18, 2023
            Full-Life Technologies Signed an Agreement to Acquire Focus-X Therapeutics to Advance Peptide-Focused Radiopharmaceutical Pipeline

              Full-Life Technologies Signed an Agreement to Acquire Focus-X Therapeutics to Advance Peptide-Focused Radiopharmaceutical Pipeline

              • November 29, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.